Tesla Inc. is very close to achieving level 5 autonomous driving technology, Elon Musk, CEO, Tesla Inc. said, “I’m extremely confident that level 5 or essentially complete autonomy will happen and I think will happen very quickly”.
Tesla in April had already surprised investors by the performance of the new sport utility vehicle, Model Y. Only US vehicle factory in California was remained closed during the lockdown form the March end to early May. Tesla sold nearly 15,000 China-made Model 3 sedans last month and had made a solid delivery of 88,400 vehicles in the first quarter. The auto sale is also affected by a pandemic which raised the expectations to be profitable in the second quarter. Along with this, Tesla will mark four consecutive profitable quarters and as a result being added in S&P 500 index.
Musk said, “I remain confident that we will have the basic functionality for level 5 autonomy complete this year”. Currently, Tesla builds cars with an Autopilot driver-assistance system and also developing new heat-projection or cooling systems to enable more advanced computers having the capability to navigate roads without any driver input.
Automakers and tech companies are investing billions in the autonomous driving industry. Technology would take time for getting ready and the public to trust autonomous vehicles fully.
Power Mech Shares Skyrocketed 17% on Order from BHEL

Shares of Power Mech Projects Ltd skyrocketed 17% on Monday, 24 March, after the company announced securing an order worth Rs 579 crore from BHEL.
In its regulatory filing, the company said that they had secured an order from Bharat Heavy Electricals Ltd (BHEL) for civil structural and architectural works, which has to be completed in a period of 32 months from the date of receipt.
On 25 February 2025, Power Mech announced that it had secured a Rs 164.63 crore contract from BHEL for the DVC Koderma TPS Phase-II-EPC project (2 × 800 MW). The scope includes design, engineering, main supply, mandatory spares, civil works, and erection & commissioning (E&C). The project is to be completed within 30 months from the issuance of the Letter of Award.
Additionally, Power Mech’s management is actively pursuing tenders to meet its Rs 3,000 crore target in new orders by March 2025. The company has also emerged as the L1 bidder for the 49 km Deoghar Bypass Highway project in Jharkhand, valued at Rs 973 crore under the hybrid annuity model (HAM).
As a leading engineering and construction firm, Power Mech specializes in the erection, testing, and commissioning (ETC) of boilers, turbines, and generators, along with balance of plant (BOP), civil works, and operation & maintenance (O&M). The company undertakes projects of various scales and complexities across India and abroad, including:
- Ultra-mega power projects
- Supercritical and subcritical thermal power projects
- Heat recovery and waste heat recovery steam generators
- Circulating fluidized bed combustion steam generators
- Gas turbine generators and hydroelectric plants
- Renovation, modernization, and annual maintenance of operational plants
- Comprehensive civil works in domestic and international markets
At 3:30 pm, the shares of Power Mech were trading 16.43% higher at Rs 2,525.10 on NSE.
Ask the analyst & get instant answer about Power Mech projects Ltd.
Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!
Biocon Shares Surge 2% on Approval from USFDA for Blood Pressure Drug

Shares of Biocon Ltd were trading in the green and 2% higher on 24 March after the company’s subsidiary announced securing approval from the USFDA for norepinephrine bitartrate injection.
Biocon Pharma has expanded its portfolio of complex injectable products with the approval of norepinephrine bitartrate injection (4 mg/4 mL, 1 mg/mL) in a single-dose vial, the company announced in a stock exchange filing.
Norepinephrine bitartrate injection is a critical drug used to elevate blood pressure in adults experiencing acute hypotension. With this approval, Biocon Pharma is now authorized to commercialize the product in the US market, strengthening its presence in the complex drug segment.
Earlier, on 4 March, the company secured final USFDA approval for two key drug products:
- Lenalidomide Capsules (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg) – Used in the treatment of multiple myeloma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, and myelodysplastic syndromes (MDS)-related anaemia in adults.
- Dasatinib Tablets (20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg) – Approved for treating Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in adults and children aged one year and above.
Additionally, Biocon Pharma received tentative USFDA approval for its Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP, available in 2.5 mg, 10 mg, 15 mg, and 20 mg strengths.
Rivaroxaban is prescribed for treating deep vein thrombosis (DVT) and pulmonary embolism (PE) and reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, among other conditions.
At 2:58 pm, the shares of Biocon were trading 0.89% higher at Rs 350.60 on NSE.
Got Biocon Ltd Questions? The Analyst is Ready.
Tired of guessing stocks to trade in daily?
Unicorn Signals empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Unicorn Signals app today and take control of your investments!
NCC Shares Surge 3% on Bagging Order Worth Rs 1,480 Crore

Shares of NCC Ltd surged 3% on 24 March after the company announced securing a letter of acceptance (LoA) from Bihar Medical Services and Infrastructure Corporation Limited to the company for the redevelopment of Darbhanga Medical College & Hospital in Laheriasarai.
In its regulatory filing, the company said, “Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, today the Company has received Letter of Acceptance dated 21 March 2025 from Bihar Medical Services & Infrastructure Corporation Limited for Redevelopment of Darbhanga Medical College & Hospital at Laheriasarai, Darbhanga.”
The project must be completed within 42 months and has a total value of Rs 1480.34 crore.
The company was recently given a Rs 2,129.6 crore contract by the Andhra Pradesh Capital Region Development Authority.
In an exchange filing, the company said, “We are pleased to inform that, the Company has received Letter of Acceptance dated 19 March, 2025, from Andhra Pradesh Capital Region Development Authority for construction of roads, drains, water supply, sewage, utility ducts for power and ICT, reuse waterline and avenue plantation etc. at Zone-12 villages area in Amaravati Capital City, Andhra Pradesh.”
NCC will construct roads, drains, water supply, sewage, power and ICT utility ducts, reusing water lines, and avenue plantations in accordance with the order’s terms using a lump sum contract (percentage tender).
NCC Ltd. is an Indian company that develops buildings and infrastructure. In a range of industries, including commercial, residential, industrial, and transportation infrastructure, it is well known for completing large-scale projects. The company builds power plants, water supply systems, roads, highways, bridges, and urban and rural development projects.
By putting quality, safety, and sustainability first, NCC Ltd. has built a strong reputation for finishing difficult projects on time and within budget. Its diverse portfolio includes both governmental and private sector clients, and it operates both domestically and internationally in India.
At 1:32 pm, the shares of NCC were trading 1.16% higher at Rs 208.43 on NSE.
NCC Ltd Insights? Let the Analyst Guide You.
Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!
RailTel Corporation Shares Skyrocketed 9% on Receiving Order From HPCL

Shares of RailTel Corporation of India Ltd skyrocketed on 24 March after receiving an order for Rs 25.15 crore from Hindustan Petroleum Corporation.
The agreement is valued at Rs 25.15 crore (without tax) and covers the renewal of existing MPLS and ILL links for five years. It also includes the potential for further connections, contingent on practicality. Following 1 April 2025, the agreement is set to expire on 31 March 2030.
This follows RailTel’s recent disclosure that the Ministry of Defence had issued a work order for OFC Laying Work, valued at Rs 16.89 crore (tax included).
The Board of Directors of the company had approved a second interim dividend of Rs 1 per share of the current fiscal year and had set 2 April 2025 as the record date and 9 April 2025 as the dividend payment date.
In Q3FY25, RailTel’s net profit increased by 5% year over year to Rs 65 crore. Revenue increased 15% year over year at Rs 768 crore. In contrast, EBITDA fell 6.6% YoY to Rs 121 crore from Rs 129.7 crore in the same period the previous year. Consequently, the EBITDA margin dropped to 15.8% from 19.4% in Q3FY24.
At 12:28 pm, the shares of RailTel Corp were trading 5.62% higher at Rs 527.15 on NSE.
Wondering About RailTel Corporation of India Ltd? The Analyst Has Answers.
Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!
Godrej Properties Shares Gained 2% on Acquiring Land in Bengaluru

The share price of Godrej Properties Ltd rose by more than 2% on 24 March after the business purchased 10 acres of land in Bengaluru.
In its regulatory filing, the company said, “announced the acquisition of ~ 10 acres of land in Yelahanka, Bengaluru, which is estimated to have a developable potential of ~ 1.5 million square feet of saleable area, for residential development, with an estimated revenue potential of ~ Rs 2,500 crore.”
The project is set to feature approximately 1.5 million square feet of developable space, primarily comprising premium residential units in various configurations, along with high-street retail outlets.
Situated along NH-44, the land is in a strategic, high-growth zone. Yelahanka, one of North Bengaluru’s fastest-growing residential and commercial hubs, is well-connected to Bengaluru International Airport Road and offers robust social and civic infrastructure, including multi-speciality hospitals, shopping complexes, residential townships, and upcoming commercial developments.
The area also enjoys seamless connectivity to Kempegowda International Airport, the Outer Ring Road (ORR), and key IT hubs, making it a prime location for residential and mixed-use projects.
This acquisition reinforces Godrej Properties’ commitment to expanding in Bengaluru’s high-potential markets.
Gaurav Pandey, MD & CEO of Godrej Properties, stated that Yelahanka is a key micro-market for the company, and adding this land parcel aligns with its strategy of strengthening its presence across India’s major cities.
Earlier this month, the company ended its agreement with TCM (formerly Travancore Chemical & Manufacturing Co. Ltd.) to develop a plot of land in Thrikkakara, Kochi.
The company sold inventory in the Godrej Evergreen Square project in Hinjewadi, Pune, in February for almost Rs 1,000 crore, just four months after acquiring the site.
At 11:27 am, the shares of Godrej properties were trading 1.80% higher at Rs 2,182.45 on NSE.
Curious About Godrej Properties Ltd? Ask the Analyst.
Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!